• OmniGuide Holdings Completes Merger of OmniGuide, Inc. and Domain Surgical, Inc.

    7 November 2016
    617 Views

    Lexington, MA- August 10, 2016 – OmniGuide Holdings, Inc., the parent company of OmniGuide, Inc., a leader in flexible fiber CO2 laser surgery, announced today that it has signed an agreement to merge with Domain Surgical Inc., to enhance its advanced energy surgical portfolio.

    The merger with Domain Surgical, Inc., Salt Lake City, UT broadens the ability to bring safe and precise surgical technologies to more surgeons and patients. Domain Surgical is the maker of the FMX Ferromagnetic Surgical System, a surgical platform that uses ferromagnetic technology to precisely and safely cut, coagulate and seal tissue; with minimal injury to surrounding tissue as compared to other surgical technologies.

    Despite advances in technology, surgical interventions can cause undesired collateral damage to healthy tissue, which can lead to post-operative pain, prolonged patient recovery and complications. Domain Surgical’s patented ferromagnetic technology is based on the principle of ferromagnetic heating. Simply described, heat is produced when a material having magnetic “domains” is exposed to an alternating magnetic field. The result is a surgical system that provides consistent cutting and hemostasis, with much less thermal injury than traditional electrosurgery, without passing potentially dangerous electrical current through the patient.

    OmniGuide’s combined technologies now deliver a variety of surgical applications, to ENT and GYN surgeons, ranging from precision cutting and ablation, to quick hemostatic dissection, to reliable vessel sealing; all with optimized precision and safety, without passing electrical current through the patient.

    In conjunction with the merger, John T. Buhler, has been named President and CEO of OmniGuide Holdings. Mr. Buhler has extensive experience in the technology, life-sciences and healthcare fields with a career spanning 30+ years. He has been the CEO/COO of three public and two private companies, completed numerous rounds of financing, done ˜$1 billion in mergers and acquisitions, and most recently merged RF Surgical Systems, Inc. with Medtronic. He has successfully completed four turnarounds, with each entity becoming a high growth/profitable business in its discipline. Mr. Buhler has an impressive history generating new revenue streams, building business, and increasing market share for multi-million and multi-billion dollar international high-technology corporations. His businesses have demonstrated the ability to penetrate new markets and strengthen competitive positioning, design and direct high-impact strategic plans, define visions and transform concepts into lucrative workable realities.

    “Both OmniGuide and Domain Surgical technologies are known for extreme precision and for minimizing unintended collateral damage to healthy tissue during complex surgical procedures. Further, both technologies are designed to increase patient safety and improve clinical outcomes,” said Mr. Buhler. “Merging the companies provides an expanded advanced energy product portfolio that delivers precise cutting, ablation, dissection, and vessel sealing capabilities across numerous sub-specialties. I am excited to be a part of this dynamic team as we grow the company moving forward.”

    ABOUT OmniGuide Surgical
    OmniGuide Surgical is an advanced energy company focused on surgeons and patients. OmniGuide’s technologies deliver energy in a safe, reliable manner resulting in the preservation of healthy tissue.

    Continue Reading
  • Domain Surgical Receives CE Mark Approval for its FMsealer Vessel Sealing Instruments

    7 November 2016
    385 Views

    FMsealers provide surgeons with reliable vessel sealing while minimizing thermal damage to surrounding tissue. With approval, FMsealers are now cleared for sale and clinical use in Europe.

    SALT LAKE CITY (May 12, 2016) – Domain Surgical, a leading manufacturer of advanced thermal surgical instruments, announced today that the company has received CE Mark approval for its FMsealer Open Shears and FMsealer Laparoscopic Shears vessel sealing instruments.

    FMsealers are multifunctional thermal surgical instruments that use ferromagnetic technology to efficiently seal and divide tissue with minimal lateral thermal spread in both open and laparoscopic surgical procedures. FMsealers can be used in any open or laparoscopic surgical procedure where ligation of vessels, including lymph vessels, is desired. FMsealers are used to seal and ligate vessels up to 7mm in diameter, and tissue bundles as large as will fit into the jaws of the instrument.

    “We are pleased to announce CE Mark approval for the FMsealer instruments,” said David McNally, President and CEO of Domain Surgical. “FMsealer Open Shears have already been successfully used in open surgery in the United States. Surgeons using the instrument appreciate its ergonomics, speed, and reliability. The FMsealer can be instantly swapped out with our FMwand precision dissection instrument at any time during a surgery, providing unequaled precision in dissection and vessel sealing; while utilizing just a single source of advanced surgical energy. With CE Mark approval, we now look forward to bringing the clinical benefits of ferromagnetic vessel sealing to our customers in Europe.”

    CE Mark approval for FMsealer instruments was based on extensive laboratory and pre-clinical studies with leading surgeons. The results of these studies demonstrated that FMsealers offer consistent and reliable vessel sealing, while imparting less thermal damage to surrounding tissues than leading competitive instruments. FMsealers also offer quicker sealing and dividing cycles than leading competitive instruments.

    The FMsealer is a component of Domain Surgical’s FMX Ferromagnetic Surgical System. The FMX System uses ferromagnetic technology to precisely cut, coagulate, and seal tissue and vessels; with a fraction of tissue injury compared to other surgical technologies, and without passing electrical current through the patient. The FMX system is used in numerous surgical sub-specialties including cardiothoracic, head & neck, neurosurgery, surgical oncology, and more.

    About Domain Surgical, Inc.
    Domain Surgical, Inc. is a privately held company based in Salt Lake City, Utah. The company has commercialized a surgical platform for precise cutting, coagulation, and sealing of tissue and vessels. Domain Surgical’s patented technology produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and reliability in the most critical surgical applications. For more information, please visit domainsurgical.com.

    Continue Reading
  • Domain Surgical Issued 26th Patent

    7 November 2016
    356 Views

    Latest patents cover the control of ferromagnetic heating and the combination of ferromagnetic technology with other surgical modalities.

    SALT LAKE CITY (February 24, 2016) – Domain Surgical, a leading manufacturer of advanced thermal surgical instruments, announced today the issuance of four new patents by the U.S. Patent and Trademark Office covering the control of ferromagnetic heating and combining ferromagnetic technology with other modalities for use in surgical procedures.

    The patents issued are numbers:

    • 9,265,553 – Inductively Heated Multi-Mode Surgical Tool
    • 9,265,554 – Thermal Adjustable Surgical System and Method
    • 9,265,555 – Multi-Mode Surgical Tool
    • 9,265,556 – Thermally Adjustable Surgical Tool, Balloon Catheters and Sculpting of Biologic Materials

    These most recent patent issuances bring Domain Surgical’s total number of issued U.S. patents to 26. Additional U.S. and foreign patents are pending.

    “These latest patents represent our ongoing commitment to grow the extensive intellectual property portfolio surrounding our novel thermal surgical technology,” stated David McNally, President and CEO of Domain Surgical. “Domain Surgical has invested heavily in securing patents covering ferromagnetic technology, and we plan to leverage this intellectual property as we continue to expand our product line into a broader range of surgical sub-specialties.”

    Domain Surgical’s FMX Ferromagnetic Surgical System uses ferromagnetic technology to precisely cut, coagulate, and seal tissue; with a fraction of tissue injury compared to other surgical technologies, and without passing electrical current through the patient. The FMX system is used in numerous surgical sub-specialties including cardiothoracic, head & neck, neuro, surgical oncology, and more.

    About Domain Surgical, Inc.
    Domain Surgical, Inc. is a privately held company based in Salt Lake City, Utah. The company has commercialized a surgical platform for precise cutting and coagulation of soft tissue. Domain Surgical’s patented technology produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and predictability in the most critical surgical applications. For more information, please visit domainsurgical.com.

    Continue Reading
  • FMsealer™ Vessel Sealing Instrument Used in First Surgical Procedure

    7 November 2016
    414 Views

    prod-fm3001FMsealer Open Shears successfully used in surgery by Dr. Robert Glasgow at the University of Utah Hospital during a transhiatal esophagogastrectomy for esophageal cancer

    SALT LAKE CITY (January 19, 2016) – Domain Surgical, a leading manufacturer of advanced thermal surgical instruments, announced today that its FMsealer Open Shears vessel sealing device was successfully used for the first time in surgery on a human patient.

    The FMsealer Open Shears is the newest component of the medical design award-winning FMX Ferromagnetic Surgical System. The FMX System brings safer, more precise advanced energy technology to many of the most critical and challenging surgical procedures. The FMsealer is an intelligent, multifunctional thermal vessel sealing instrument that precisely and reliably seals and divides vascularized tissue, blood vessels, and lymphatics in open surgical procedures with less collateral thermal damage than competitive devices.

    Robert E. Glasgow, M.D., FACS used the FMsealer during a transhiatal esophagogastrectomy at the University of Utah Hospital. Dr. Glasgow is Professor, Vice Chairman of Clinical Operations and Quality, and Chief Value Officer for the Department of Surgery at the University of Utah. Dr. Glasgow, along with his colleagues and resources at the University of Utah, collaborated with Domain Surgical during the product development and validation of the clinical effectiveness of the FMsealer, leading to FDA clearance.

    “The FMsealer exceeded my expectations for clinical performance in this complex operation,” stated Dr. Glasgow. “As compared to ultrasonic and bipolar-based devices, it was highly efficient. It was highly reliable. It was ergonomically superior. As seen in the validation studies, there was less heat transfer and less thermal damage to adjacent tissue. The FMX technology allows the surgeon to conduct an entire operation using one energy platform. The plug and play capability allowed me to switch easily between the FMwand, which is the ideal device for fine hemostatic dissection within tissue planes, and the FMsealer, which proved highly effective in sealing vascularized tissue.”

    “Dr. Glasgow played a vital role in the clinical development and validation of the FMsealer Open Shears, and it was appropriate that he perform the first human surgery using the instrument,” stated David McNally, President and CEO of Domain Surgical. “The launch of the FMsealer Open Shears represents the culmination of several years of collaborative work with surgeons at the University of Utah and The Utah Science Technology and Research Initiative (USTAR). The FMsealer, along with the currently available FMwand dissection instrument, represent an entire surgical platform based on ferromagnetic technology.”

    Over the next few weeks, the FMsealer Open Shears will be used in a variety of surgical procedures at many leading medical facilities across the United States. The FMsealer is also expected to be available for use in select countries in Europe in the coming months. A video of the procedure performed with the FMsealer can be viewed athttp://domainsurgical.com/technology/videos/detail.cfm?ID=1076.

    About Domain Surgical, Inc.
    Domain Surgical, Inc. is a privately held company based in Salt Lake City, Utah. The company has commercialized a surgical platform for precise cutting, coagulation, and sealing of tissue and vessels. Domain Surgical’s patented technology produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and predictability in the most critical surgical applications. For more information, please visit domainsurgical.com.

     

    Continue Reading
  • Domain Surgical Launches New Website Optimized for Mobile Interaction

    7 November 2016
    416 Views

    The newly designed domainsurgical.com website features a mobile-optimized interface with relevant clinical content designed for surgeons and hospital administration staff.

    SALT LAKE CITY (January 4, 2016) – Domain Surgical, a leading manufacturer of advanced thermal surgical instruments, announced today that it has launched its newly designed website at domainsurgical.com. The full-featured website has been designed to deliver an optimized interactive experience, especially when viewed with mobile devices such as phones and tablets.

    Domain Surgical’s website is designed to assist surgeons, surgical staff, hospital administrators, distributors, and investors in understanding the company’s advanced-energy thermal surgical platform, the FMX Ferromagnetic Surgical System. The website focuses on delivering content to clearly illustrate how ferromagnetic surgical technology works, in-depth information on the complete line of FMX surgical instruments, and the clinical evidence of improved patient outcomes when using the FMX System.

    A growing number of visitors to the domainsurgical.com website access site content through a mobile device. The new site has been completely redesigned to provide an engaging and consistent viewing experience for viewers accessing the site through mobile devices and standard desktop computers.

    A central component of the domainsurgical.com website is the media library, which contains a large number of surgical videos showcasing surgeon experiences using FMX surgical instruments in a variety of surgical sub-specialties. Many videos include narration by the surgeon performing the procedure. The library can be organized based on surgical instrument or by surgical sub-specialty, depending on the user’s preference. The library provides an opportunity for surgeons who may be interested in using the FMX System to view familiar procedures being performed with Domain Surgical’s surgical instruments.

    The new website also features product and clinical information regarding Domain Surgical’s line of advanced-energy vessel sealing devices, FMsealer, that was announced last year. The website provides an up-to-date product catalog, downloadable Directions for Use, a library of published clinical evidence, upcoming tradeshow exhibit calendar, and a demonstration request form.

    About Domain Surgical, Inc.
    Domain Surgical, Inc. is a privately held company based in Salt Lake City, Utah. The company has commercialized a surgical platform for precise cutting and coagulation of soft tissue. Domain Surgical’s patented technology produces surface-only tissue effects without passing electrical energy through the patient, and is designed to provide unparalleled safety and predictability in the most critical surgical applications. For more information, please visit domainsurgical.com.

    Continue Reading
  • Women’s Care Florida among first 100 DYSIS users in USA

    7 November 2016
    402 Views

    Women’s Care Florida among first 100 U.S. OB-GYN practices implementing advanced cervical imaging technology

    First locations in Tampa Bay to standardize colposcopy after abnormal Pap smears  

     

    Edinburgh, UK, September 26, 2016 – DYSIS Medical Ltd. (DYSIS), an innovative women’s health company, announced today that Women’s Care Florida has implemented the DYSIS Advanced Cervical Imaging System for early detection of cervical cancer.

    Women’s Care Florida, one of the largest OB-GYN groups in Florida, added the DYSIS advanced digital colposcope to two of their locations in Brandon and Tampa, making them one of the first 100 practices to adopt this technology in the United States.

    “Women’s Care Florida decided to implement DYSIS because this is cutting-edge, state-of-the-art colposcopic technology,” said Dr. Martha E. Kapitz, a Women’s Care Florida physician.

    Colposcopy, which can be subjective and has remained unchanged for decades, is an exam performed after a woman has an abnormal Pap smear.  DYSIS has advanced the standard colposcopy technique by using computer-aided mapping.

    “With the DYSIS technology, it improves detection by actually mapping out areas of the cervix that look most suspicious,” explained Dr. Kapitz.  DYSIS quantifies colposcopy by capturing images and creating a color-coded map, highlighting the more intense acetowhitened areas. Physicians can then use a guided biopsy procedure to assist in identifying the best areas to biopsy.

    DYSIS further helps practices like Women’s Care Florida with standardizing the subjective colposcopy procedure, which is important to physicians in terms of improving outcomes and providing the best care to their patients.

    “Cervical detection is something that we have already been doing, but now we’re just bringing it up to the next level to improve detection for our patients and improve overall care of women,” said Dr. Kapitz.

    “We are excited to be working with Women’s Care Florida, a well-renowned OB-GYN physician group in Florida that recognizes the importance of advancing today’s cervical screening technology. By standardizing the currently subjective colposcopy procedure, we can help improve care for women,” said Kim Stebbings, US President of DYSIS Medical.

    About Women’s Care Florida

    Women’s Care Florida, LLC (WCF) is a multi-specialty, women’s health, physician group offering patient care services in obstetrics, gynecology, gynecologic oncology, urogynecology, gynecologic and breast pathology, breast surgery and maternal-fetal medicine. The group has over 200 providers in over 60 outpatient locations, including a women’s services laboratory and a breast center.

     

    About DYSIS Medical

    DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.abnormalpapsmear.com or call 844-DYSISMED.

    About the DYSIS colposcope

    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

    About cervical cancer

    Each year, more than 12,000 women are diagnosed in the US with cervical cancer and over 4,000 will die.  Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

    Continue Reading
  • Arizona Oncology implements DYSIS

    7 November 2016
    415 Views

    Arizona Oncology implements advanced cervical imaging technology to assist with the early detection of cervical cancer

    September 28th is National Women’s Health and Fitness Day and women are encouraged to take control of their health

    Scottsdale, Ariz. (September 22, 2016) – Arizona Oncology, one of the largest medical groups in Arizona devoted to cancer care and a practice in The US Oncology Network, is the first in Arizona to utilize the latest technology and advancement in the early detection of cervical cancer and pre-cancers. The practice has implemented the DYSIS® Advanced Cervical Imaging System. This advanced digital colposcope, an instrument for examining the cervix, has computer-aided mapping technology and can enhance a doctor’s ability to diagnose and manage cervical neoplasia, precancerous cells, by detecting changes in a woman’s cervix after an abnormal Pap smear.

    More than 12,000 women are diagnosed with cervical cancer each year in the U.S., and many of those women will be among the thousands participating in local health and fitness events across the country on Wednesday, September 28th. One goal of the National Women’s Health and Fitness Day is to encourage women to take control of their health and to gather information to help them make smart choices related to their health. Arizona Oncology adopted the DYSIS colposcope technology to not only assist physicians in identifying pre-cancerous or cancerous cells on the cervix, but to also help women understand their colposcopy exam through high-resolution imagery and easy-to-read color-coded maps of the cervix provided by DYSIS technology.

    “The new DYSIS technology helps us better pinpoint questionable areas on the cervix that may need biopsy,” said Dr. Mike Janicek, gynecologic oncologist at Arizona Oncology. “We can share images and the color-coded maps with women in real time and immediately following the exam. We can provide color digital or paper copies of the exam images for patients and their referring providers. Our goal is have our patients feel reassured and involved in their healthcare when having a DYSIS colposcopy exam, and referring doctors can feel more involved in the evaluation process as well.”

    Colposcopy, which can be subjective and has remained unchanged for decades, is an exam performed after a woman has an abnormal Pap smear. DYSIS has advanced the standard colposcopy technique by using digital imaging technology that assists physicians in detecting changes in a woman’s cervix and helping guide biopsy selection to determine the best course of treatment to prevent cervical cancer. “We are excited to be working with Arizona Oncology, a distinguished oncology specialty group that recognizes the importance of advancing today’s cervical screening technology,” said Kim Stebbings, U.S. President of DYSIS Medical. “By standardizing the currently subjective colposcopy procedure, we can help improve care for women and help them take control of their health.”
    
    About Arizona Oncology
    Arizona Oncology is one of the largest medical groups in Arizona. With more than 75 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic, and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Chandler, Deer Valley, Estrella, Flagstaff, Glendale, Green Valley, Nogales, Peoria, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson. Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit ArizonaOncology.com. Arizona Oncology is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence based cancer care. As an affiliate of The US Oncology Network, Arizona Oncology is united with more than 1,000 physicians nationwide. Arizona Oncology participates in clinical trials through US Oncology Research, which has played a role in more than 60 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visitwww.usoncology.com.
    
    About DYSIS Medical
    DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit:www.dysismedical.com or call 844 DYSISMED.

    About the DYSIS colposcope
    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

    About cervical cancer
    Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

    Media Contacts
    Amy Robertson 480-789-2986 Amy.Robertson@usoncology.com

    Continue Reading
  • First Data from largest colposcopy trial

    7 November 2016
    365 Views

    DYSIS Medical Ltd. (DYSIS), an innovative women’s health company that offers a new cervical imaging technology (dynamic spectral imaging) for women with abnormal Pap smears, announced today it will present initial findings from the IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) at the Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG), to be held in Washington, D.C., May 14-17.

    The objective of the 11,000-patient IMPROVE-COLPO study is to measure outcome improvements in detection of cervical neoplasia (pre-cancers) when using the DYSIS Advanced Cervical Imaging System compared to standard methods. The results from two community clinics to be presented at ACOG, show that biopsies assisted by dynamic spectral imaging and mapping of the cervix increased detection of high-grade neoplasia by 36.8 percent over standard colposcopic visualization. DYSIS also recently presented early data from nearly 3,000 women with low-grade pap smears that showed detection of patients with high-grade disease increased by a third in the DYSIS study arm compared to the standard care arm.

    “Colposcopy, which can be very subjective, is the diagnostic procedure performed after an abnormal Pap smear,” said DYSIS Medical’s Clinical Manger, Dr. Manolis Papagiannakis. “DYSIS advances standard techniques by using digital imaging technology that can help clinicians standardize colposcopy and improve the detection of pre-cancerous and cancerous lesions. We look forward to sharing initial findings from the IMPROVE-COLPO study with the attendees of the ACOG 2016 Annual Meeting.”

    More than 12,000 U.S. women are diagnosed with cervical cancer annually and 4,300 die from the disease. The DYSIS digital colposcope can enhance a doctor’s ability to diagnose and manage cervical neoplasia, by detecting changes in a woman’s cervix and helping to guide biopsy selection and the best course of treatment to prevent cervical cancer.

    “We are excited that DYSIS is now in use by clinicians around the globe, is included in UK cervical screening guidelines and is reimbursable by insurance,” said DYSIS Chief Executive Officer, Alastair Atkinson. “Standardizing this variable and subjective procedure can help improve care for women – and with earlier treatment, has the potential to help prevent cervical cancer.”

    About DYSIS Medical
    DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit:http://www.dysismedical.com or call 844-DYSISMED.

    About the DYSIS colposcope
    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

    About cervical cancer
    Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

    DYSIS Medical Ltd. (DYSIS), an innovative women’s health company that offers a new cervical imaging technology (dynamic spectral imaging) for women with abnormal Pap smears, announced today it will present initial findings from the IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) at the Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG), to be held in Washington, D.C., May 14-17.

    The objective of the 11,000-patient IMPROVE-COLPO study is to measure outcome improvements in detection of cervical neoplasia (pre-cancers) when using the DYSIS Advanced Cervical Imaging System compared to standard methods. The results from two community clinics to be presented at ACOG, show that biopsies assisted by dynamic spectral imaging and mapping of the cervix increased detection of high-grade neoplasia by 36.8 percent over standard colposcopic visualization. DYSIS also recently presented early data from nearly 3,000 women with low-grade pap smears that showed detection of patients with high-grade disease increased by a third in the DYSIS study arm compared to the standard care arm.

    “Colposcopy, which can be very subjective, is the diagnostic procedure performed after an abnormal Pap smear,” said DYSIS Medical’s Clinical Manger, Dr. Manolis Papagiannakis. “DYSIS advances standard techniques by using digital imaging technology that can help clinicians standardize colposcopy and improve the detection of pre-cancerous and cancerous lesions. We look forward to sharing initial findings from the IMPROVE-COLPO study with the attendees of the ACOG 2016 Annual Meeting.”

    More than 12,000 U.S. women are diagnosed with cervical cancer annually and 4,300 die from the disease. The DYSIS digital colposcope can enhance a doctor’s ability to diagnose and manage cervical neoplasia, by detecting changes in a woman’s cervix and helping to guide biopsy selection and the best course of treatment to prevent cervical cancer.

    “We are excited that DYSIS is now in use by clinicians around the globe, is included in UK cervical screening guidelines and is reimbursable by insurance,” said DYSIS Chief Executive Officer, Alastair Atkinson. “Standardizing this variable and subjective procedure can help improve care for women – and with earlier treatment, has the potential to help prevent cervical cancer.”

    About DYSIS Medical
    DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit:http://www.dysismedical.com or call 844-DYSISMED.

    About the DYSIS colposcope
    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

    About cervical cancer
    Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

    Continue Reading
  • DYSIS Announces Preliminary Findings From Largest U.S. Colposcopy Community Study at ASCCP 2016

    7 November 2016
    396 Views

    Three abstracts presenting data from the study have been selected for poster presentations

     

     

    TAMPA, Fla., April 12, 2016 – DYSIS Medical, a leading medical device company active in women’s health, announced today that three abstract submissions to the 2016 Annual Meeting of the American Society for Colposcopy and Cervical Pathology (ASCCP) have been accepted for poster presentations. The abstracts summarize initial findings from the ongoing 11,000-patient IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) study and will be presented at the meeting to begin April 13, in New Orleans, LA.  During the meeting, DYSIS Medical will also showcase its advanced cervical imaging system.

     

    More than 12,000 U.S. women are diagnosed with cervical cancer annually and 4,300 die from the disease. Colposcopy, which can be very subjective, is the diagnostic procedure performed after an abnormal Pap smear to detect precancerous areas. The objective of the IMPROVE-COLPO study, which is the largest U.S. colposcopy community study to date, is to measure outcome improvements with the DYSIS Advanced Cervical Imaging System compared to standard colposcopy.

     

    “Cervical cancer is preventable with early detection, and we are very excited to be at the forefront of the technology that can enhance a doctor’s ability to diagnose and manage cervical neoplasia, and ultimately to prevent cervical cancer,” said DYSIS Medical’s Clinical Manager, Dr. Manolis Papagiannakis. “The DYSISmap and the documentation images can add real value to doctors managing their patients’ health, and we are looking forward to sharing some of the initial findings from the IMPROVE-COLPO study with ASCCP Annual Meeting attendees.”

     

    “The DYSIS advanced cervical imaging system has brought real value to my practice by helping me identify lesions not recognized with standard colposcopy, and to also manage young women more conservatively,” stated Dr. Aarathi Cholkeri-Singh, one of the principal investigators in the IMPROVE-COLPO study.  “The high resolution images, electronic record documentation and ability to share the DYSISmap with patients has made a difference in ensuring that my patients understand their condition and are compliant to my follow-up care plan.”

     

    About DYSIS Medical

    DYSIS Medical has its global headquarters in Edinburgh and US Headquarters in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com or call 844-DYSISMED.

     

    About the DYSIS colposcope

    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically using Dynamic Spectral Imaging and producing a map of the cervix, which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

     

     

    About cervical cancer

    Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

     

    Continue Reading
  • DYSIS Medical Signs Significant Deal

    7 November 2016
    389 Views

    contact-dysisDYSIS Medical Signs Significant Deal with ITEM Medical Technologies to Support National Screening Programme in Turkey

     

    DYSIS Colposcope to be incorporated into national cervical screening programme

     

    Edinburgh, UK – 1 March 2016− DYSIS Medical Ltd. (DYSIS) today announces that it has signed a significant contract with medical technology distributor, ITEM Medical Technologies as part of the national cervical screening programme in Turkey. No financial details have been disclosed.

     

    As part of plans to advance the country’s cervical screening programme, the Turkish Ministry of Health selected DYSIS’s Colposcope over other technologies.  The aim is to install a DYSIS Colposcope in every City hospital in the country. ITEM Medical Technologies has purchased an initial instalment of 75 instruments from DYSIS in order to begin the roll-out during 2016.

     

    Alastair Atkinson, CEO of DYSIS, said: “This order is another clear endorsement of our technology. ITEM Medical Technologies is working closely with the Turkish Ministry of Health to bring better standards of healthcare to women. Adopting the DYSIS Colposcope will enhance Turkey’s screening programme.”

     

    Zafer Yazici, Managing Director of ITEM Medical Technologies, said: “Cervical cancer screening in Turkey is a vital component of women’s healthcare, delivered thorough approximately 1,000 screening centres.  The advantages offered by the DYSIS Colposcope were proven in the clinical evaluation that was performed and are strongly appreciated by gynaecologists.”

     

    The DYSIS Colposcope differs from traditional colposcopes by measuring the cervical epithelium, producing a map of the cervix. The DYSISmap assists the clinician with the processes of evaluating the cervix, selecting biopsy sites or performing treatment if needed. The DYSISmap technology acts as an adjunct to conventional methods.

     

    Alastair Atkinson added, “This contract builds on the strong adoption of our products in the UK, US and Middle Eastern markets where over 80,000 DYSIS examinations have now been undertaken. We continue to receive very positive feedback from consultants and we know our technology is saving women’s lives. DYSIS is proving itself as the new standard of care for cervical cancer prevention.”

     

    Sales of the DYSIS Colposcope continue to grow.  The instrument is now installed within 70 centres within selected US states and is available in the UK, northern Europe and the United Arab Emirates.

    Ends

     

     

     

     

    At the Company: Media enquiries:
    Alastair Atkinson Melanie Toyne Sewell/Gemma Howe
    DYSIS Medical, Inc. Instinctif Partners
    E: info@dysismedical.com E: dysis@instinctif.com
    T: 01506 592159 T: 020 7866 7860

     

    Notes to Editors

     

    DYSIS Medical Ltd

    DYSIS Medical, a medical devices company active within Women’s Health, has developed an advanced cervical scan which, in addition to performing traditional colposcopy examinations, uses dynamic spectral imaging to scan, quantify and map the cervix.

    www.dysismedical.com

     

    About the DYSIS colposcope

     

    The DYSIS colposcope differs from traditional colposcopes by measuring the cervical epithelium automatically, producing a map of the cervix which assists the clinician with assessing the cervix, identifying biopsy locations and performing treatment if needed.

     

    DYSIS delivers dynamic spectral imaging, in vivo quantified assessment of the cervix, high sensitivity quantified mapping of the aceto-whitening effect and HD digital imaging & video with intuitive touch screen interface. The DYSIS colposcope’s ergonomic design is compatible with all patient beds.

     

    About cervical cancer

    Worldwide, cervical cancer is the fourth most common cancer for women and the seventh most common cancer overall. While it is the only entirely preventable cancer, approximately half a million women are diagnosed with the disease every year.

    Continue Reading